高流量鼻导管湿化氧疗对稳定期慢性阻塞性肺疾病患者呼吸功能恢复的影响
Effect of humidified high-flow nasal cannula oxygen therapy on respiratory function recovery in stable COPD patients.
作者信息
Lyu Ruibing, Wang Wen, Wang Wenju, Liu Nian, Xiao Jinwen, Li Xin
机构信息
Department of PCCM, CR & WISCO General Hospital, Wuhan University of Science and Technology No. 29, Metallurgical Avenue, Qingshan District, Wuhan 430080, Hubei Province, P. R. China.
Department of Rehabilitation, CR & WISCO General Hospital, Wuhan University of Science and Technology No. 29, Metallurgical Avenue, Qingshan District, Wuhan 430080, Hubei Province, P. R. China.
出版信息
Am J Transl Res. 2022 Jun 15;14(6):4074-4081. eCollection 2022.
OBJECTIVE
To investigate the effect of humidified high-flow nasal cannula oxygen therapy (HFNC) on the application effect and respiratory functional recovery of stable COPD patients.
METHODS
The data of 116 patients with stable COPD treated in our hospital from March 2019 to January 2021 were analyzed retrospectively. Among them, 54 patients treated with conventional oxygen therapy (COT) were enrolled into the control group (CG), and the remaining 62 treated with HFNC were divided to the experimental group (EG). The clinical efficacy and adverse reactions of both groups were assessed, and the blood gas analysis indexes pH, PaO, PaCO, respiratory function indexes FEV1, FEV1%, FEV1/FVC, quality of life and motor recovery were compared.
RESULTS
After treatment, compared with the CG, the FEV1, FEV1% and FEV1/FVC in the EG were obviously higher (P<0.05). Besides, the pH and PaO in the EG were markedly higher (P<0.05), while PaCO was lower (P<0.05). The total effective rate, SGRQ scores and 6MWT in the EG were markedly higher than those in the CG (P<0.05), while the incidence of adverse reactions in the EG was lower (P<0.05).
CONCLUSION
HFNC can improve respiratory function and quality of life of stable COPD patients, with higher safety.
目的
探讨高流量鼻导管湿化氧疗（HFNC）对稳定期慢性阻塞性肺疾病（COPD）患者的应用效果及呼吸功能恢复的影响。
方法
回顾性分析2019年3月至2021年1月在我院治疗的116例稳定期COPD患者的数据。其中，54例接受传统氧疗（COT）的患者纳入对照组（CG），其余62例接受HFNC治疗的患者分为实验组（EG）。评估两组的临床疗效和不良反应，并比较血气分析指标pH、PaO、PaCO，呼吸功能指标FEV1、FEV1%、FEV1/FVC，生活质量和运动恢复情况。
结果
治疗后，与CG组相比，EG组的FEV1、FEV1%和FEV1/FVC明显更高（P<0.05）。此外，EG组的pH和PaO明显更高（P<0.05），而PaCO更低（P<0.05）。EG组的总有效率、圣乔治呼吸问卷（SGRQ）评分和6分钟步行试验（6MWT）明显高于CG组（P<0.05），而EG组的不良反应发生率更低（P<0.05）。
结论
HFNC可改善稳定期COPD患者的呼吸功能和生活质量，安全性更高。
Zotero 插件